$617 million! Which field will Frazier's new life science fund look forward to?

Frazier healthcare, a famous American venture capital company, was founded in 1991 Its core strategy is to invest in life science Since its establishment, it has raised nearly 4.8 billion US dollars and invested in more than 200 companies Since 2005, it has created 23 companies Looking back over the past year, the company has completed a number of investment, financing and acquisition activities, including the passage co founded by Dr Tachi Yamada and Dr Jim Wilson, pioneer of gene therapy Bio company; its founding mavupharma company was acquired by abbvie; arcutis, a dermatology treatment company, was successfully launched to the global market through nearly $100 million of cross investment, and successfully raised $160 million in a few months later, completing its strategic deployment in 2019 perfectly Now, the company plans to start its development in 2020 with a larger new fund It is believed that the $617 million life science fund will give them more impetus to do more, and more companies can develop new therapies with their help So which sub field of biomedical circle does Frazier like? Two thirds of the fund will be used for seed and a rounds of investments in life sciences, the company said In addition, its executive partner, Patrick heron, said in an interview that gene therapy, cell therapy, new antigens and other therapies need a lot of capital investment, which are also several areas they are increasingly concerned about He believes that Frazier expects to invest about $40 million in each company in need of support, and they will support these companies as appropriate, whether they need help in the initial stage or in the later development process The new fund could support 15 to 25 biomedical companies Gritstone oncology is a new tumor antigen therapy development company in Frazier's previous investment company It ranked sixth in the "top 10 global immunooncology start-ups 2019" released by the famous website Gen last year Two vaccines, granite and slate, developed based on new tumor antigens, have also obtained positive immunogenic activity and safety data in phase 1 clinical trials Photo source: Frazier website Let's take a look at how other biomedical companies supported by Frazier are doing today First, its acerta company has been acquired by AstraZeneca, and last year, it and forty seven, a tumor immunotherapy company, reached a clinical cooperation to evaluate the therapeutic effect of a triple combination therapy in diffuse large B-cell lymphoma (DLBCL) This innovative combination includes anti-CD47 monoclonal antibody 5f9, rituximab and targeted Btk inhibitor calsequence (acalabrutinib) Mirum invested Malalixibat, a selective ASBT inhibitor developed by pharmaceuticals, has been recognized by the US FDA as a breakthrough therapy in October last year for the treatment of pruritus in children aged 1 and over with Alagille syndrome (algs); its ignyta company was acquired by Roche at the end of 2017 for us $1.7 billion; and its Phatom co founded with Takeda company Pharmaceutical company, after one year's successful IPO, raised $182 million to continue to promote the development of innovative therapies for gastrointestinal diseases.